A review of venous thromboembolism in COVID‐19: A clinical perspective. (5th February 2021)

• Record Type: Journal Article
• Authors: Ozsu, Savas; Gunay, Ersin; Konstantinides, Stavros V.
• Is Part Of: Clinical respiratory journal. Volume 15:Number 5(2021)
• Page Start: 506
• Page End: 512
• Publication Date: 2021-02-05
• Subjects: anticoagulation -- COVID‐19 -- LMWH -- mortality -- venous thrombosis; Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Periodicals; 616.24
• DOI: 10.1111/crj.13330
• Languages: English
• ISSNs: 1752-6981

Abstract

Abstract: Coronavirus disease‐19 (COVID‐19) started in Wuhan, China in December 2019 and spread to all around the world in a short period of time. Hospitalized patients with COVID‐19 mostly could suffer from an abnormal coagulation activation risk with increased venous thrombosis events and a poor clinical course. The reported incidence rates of thrombotic complications in hospitalized COVID‐19 patients vary between 2.6 and 85% (both in non‐critically ill and critically ill patients). The risk of venous thromboembolism is not known in non‐hospitalized patients with COVID‐19. There are numerous studies and guidelines for administration of thromboprophylaxis for COVID‐19 cases. All hospitalized COVID‐19 patients should take pharmacological thromboprophylaxis if there is no contraindication. However, there is no consensus on this issue. In this review, we discussed all these approaches in a critical perspective.